Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7851383 | 0.81 | ALOX15 (0.40) | NAPRTNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL7849595 | 0.80 | NAPRT (0.39) | NAPRTKDM4EASPHKDM8NPC1 | |
| SCHEMBL27736344 | 0.80 | KDM4E (0.46) | KDM4ENPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL12497893 | 0.79 | ATR (0.38) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30563763 | 0.77 | ATR (0.50) | NPC1RAB9A | |
| SCHEMBL30563755 | 0.77 | ATR (0.50) | NPC1RAB9A | |
| SCHEMBL2920942 | 0.77 | ATR (0.50) | NPC1RAB9A | |
| SCHEMBL25193578 | 0.75 | KDM4E (0.37) | NAPRTKDM4EASPHKDM8NPC1 | |
| SCHEMBL7848782 | 0.75 | KMT2A (0.41) | NAPRTKDM4ESMN1; SMN2 | |
| SCHEMBL26604762 | 0.74 | GPR35 (0.33) | NAPRTGSK3AGSK3BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416286-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11780862-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023168203-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-8101628-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | BRAF, NRAS, RAF1 | NAPRT 1960/4885KDM4E 940/4885ASPH 3099/4885 |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, BUB1B, BUB1 | NAPRT 3672/4885KDM4E 1143/4885ASPH 2364/4885 |
| US-20230416286-A1 | INHIBITORS OF MEK KINASE | BRAF, NRAS, RAF1 | NAPRT 1960/4885KDM4E 940/4885ASPH 3099/4885 |
| US-11780862-B2 | Inhibitors of MEK kinase | BRAF, NRAS, RAF1 | NAPRT 1960/4885KDM4E 940/4885ASPH 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.